Search the GHTC website

Global health R&D delivers for Georgia

US government investment in global health R&D has delivered

$1.1 billion
to Georgia research institutions
18,400+ new jobs
for Georgia
Georgia's top USG-funded global health R&D institutions

Georgia's top USG-funded global health R&D institutions

Emory University
$524.1 million
US Centers for Disease Control and Prevention (self-funding or other agency transfers)
$316.4 million
University of Georgia (including the Center for Vaccines and Immunology)
$152.2 million
Georgia State University
$65.1 million
GeoVax Labs Inc.
$22.3 million
Georgia Institute of Technology
$9.5 million
Morehouse School of Medicine
$7.1 million
Metaclipse Therapeutics Corporation
$2.5 million
Kennesaw State University
$2 million
Mercer University
$1.8 million
Genetag Technology
$1.6 million
Georgia Regents University
$917 thousand
Pathens Inc.*
$759 thousand
$748 thousand
Zetra Biologicals LLC*
$409 thousand
$385 thousand
GeneCure Biotechnologies LLC*
$300 thousand
The Simple Vue, LLC
$300 thousand
$294 thousand
$277 thousand
Medical College of Georgia
$251 thousand
Augusta University
$179 thousand
Cyanvac LLC
$150 thousand
Foundation for Atlanta Veterans Education and Research Inc. (formerly Atlanta Research and Education Foundation)
$81 thousand
American College of Rheumatology
$58 thousand
InsectiGen Inc.
$19 thousand

Georgia's top areas of global health R&D by USG funding

Diarrheal diseases
Flioviral diseases (including Ebola, Marburg)
Neglected tropical diseases
Buruli ulcer
Helminth infections (Worms & Flukes)
Kinetoplastid diseases
Arenaviral hemorrhagic fevers (including Lassa fever)
Bacterial pneumonia & meningitis
Bunyaviral diseases (including CCHF, RVF, SFTS)
Cryptococcal meningitis
Emergent non-polio enteroviruses (including EV71, D68)
Henipaviral diseases (including Nipah)
Hepatitis B
Hepatitis C
Multi-disease/health area R&D
Other coronaviruses (including MERS, SARS)
Reproductive health
Salmonella infections
Global health R&D at work in Georgia

The Emory University School of Medicine has supported clinical trials of a promising vaccine to prevent infection with the chikungunya virus. Chikungunya is transmitted by mosquitoes and can cause persistent joint and muscle pain. The virus, originating in Africa, arrived in the Caribbean several years ago and has since infected an estimated 3 million people in the Americas, including a dozen locally acquired cases in Florida. The vaccine, which is now in late-stage trials, received “fast track” designation from the US Food and Drug Administration to accelerate its eventual review. If approved, the vaccine could be a powerful tool to protect against this debilitating disease.

  • Methodology
  • US government global health R&D investment (total to state, top funded institutions, top health areas): Authors’ analysis of USG investment data from the G-FINDER survey following identification of state location of funding recipients. Reflects funding for basic research and product development for neglected diseases from 2007 to 2022, for emerging infectious diseases from 2014–2022, and sexual and reproductive health issues from 2018 to 2022. Funding to US government agencies reflects self-funding and/or transfers from other agencies. Some industry data is anonymized and aggregated. See methodology for additional details.
  • *Organization appears to be closed/out of business.
  • Jobs created: Based on author’s analysis described above and previous analysis assessing jobs created per state from US National Institutes of Health funding. See methodology for additional details.
  • Neglected and emerging diseases: Reflects US Centers for Disease Control and Prevention data for: Chikungunya virus cases 2014–2022, Dengue virus infection cases 2010-2021, HIV diagnoses 2008–2022, Malaria cases 2007–2022, Mpox cases 2022–March 29, 2023, Tuberculosis cases 2007–2021, Viral hemorrhagic fever cases 2007-2022, and Zika virus disease cases 2015–2021.
  • Case study photo: Pan American Health Organization